Clinical trials: Meropenem
Drug Safety
Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
Adult patients with ESBL-producing Gram negative infections are randomized to receive ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups are compared.
- Trial name
- NCT01297842
- Testing
- Ertapenem, Meropenem or Imipenem
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Mahidol University
Renal Impairment
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
This is an open-label, non-randomized, single-center, single i.v. dose Phase 1 trial to evaluate the pharmacokinetics and safety of a combination of ANT3310 and meropenem in participants with different degrees of renal function…
- Trial name
- NCT06527677
- Testing
- ANT3310, Meropenem
- Where
- Germany
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Antabio
Bacterial Infection
Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
This is a Phase 4, interventional, multi-center pharmacokinetics (PK) study in up to 200 adult patients who are residing in an ICU.
- Trial name
- NCT06709521
- Testing
- Iohexol
- Where
- 10 sites in United States
- Volunteers
- 161 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Infections
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial…
- Trial name
- TANGOKIDS (NCT02687906)
- Testing
- Vabomere
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Sepsis
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis
This phase III multicentric international randomized trial is designed to compare the efficacy of Meropenem to the standard of care in infants below 90 days of age with clinical or confirmed late-onset sepsis (LOS).
- Trial name
- NeoMero-1 (NCT01551394)
- Testing
- Meropenem, Ampicillin + gentamicin or cefotaxime + gentamicin
- Where
- Italy
- Volunteers
- 272 people
- Sponsor
- PENTA Foundation
Antibiotic Resistant Infection, Critical Illness
Bolus Versus Continuous Infusion of Meropenem
This study arises from the need to optimize antibacterial drug usage to face increasing drug resistance among gram-negative pathogens in intensive care units.
- Trial name
- MERCY (NCT03452839)
- Testing
- Meropenem
- Where
- 26 sites in Croatia, Italy and 2 more
- Volunteers
- 607 people
- Sponsor
- Università Vita-Salute San Raffaele
Bacteremia Caused by Gram-Negative Bacteria
Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection
The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to third-generation cephalosporin…
- Trial name
- MERINO III (NCT04238390)
- Testing
- Ceftolozane-Tazobactam, Meropenem
- Where
- 29 sites in Australia, Italy and 3 more
- Sponsor
- The University of Queensland
Acute-On-Chronic Liver Failure
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
Acute on chronic liver failure patients are at high risk for nosocomial infections due to liver dysfunction, which impairs immune responses and increases vulnerability to infections.
- Trial name
- NCT06818565
- Testing
- Meropenem Injection, Ceftazidime-avibactam, Teicoplanin
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram…
- Conditions
- Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
- Trial name
- REVISIT (NCT03329092)
- Testing
- ATM-AVI, MTZ, MER
- Where
- 157 sites in United States, Argentina and 19 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Tuberculosis
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
A single-center, open-label clinical trial to determine the early bactericidal activity (EBA) and safety of the combination of meropenem and amoxicillin/clavulanate plus pyrazinamide vs.
- Trial name
- TB_COMBO_01 (NCT04629378)
- Testing
- Meropenem Injection, Amoxicillin Clavulanate, Pyrazinamide
- Where
- South Africa
- Volunteers
- 22 people
- Sponsor
- TASK Applied Science
Sepsis, Infection, Bacterial
Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy
This prospective clinical study will investigate if antibiotic concentrations in patients with severe infections can be monitored by the UV-VIS spectroscopy.
- Trial name
- NCT04282785
- Testing
- Concentration monitoring of antibiotics in plasma
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Uppsala University
Febrile Neutropenia
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
The study proposes a planned, double-blind, non-inferiority clinical trial involving patients with febrile neutropenia and risk of extended-spectrum beta-lactamase (ESBL) infection.
- Trial name
- CLEMENT (NCT06342115)
- Testing
- Ceftolozane-Tazobactam, Meropenem
- Where
- Brazil
- Volunteers
- 55 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Complicated Urinary Tract Infection, Acute Pyelonephritis
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
- Trial name
- NCT04979806
- Testing
- Cefepime-zidebactam (FEP-ZID), Meropenem
- Where
- 48 sites in United States, Bulgaria and 7 more
- Volunteers
- 530 people
- Sponsor
- Wockhardt
Peritonitis Bacterial, Liver Cirrhosis
Meropenem Pharmacokinetics in Spontaneous Bacterial Peritonitis
The emergence of multidrug-resistant bacteria has increased the use of meropenem in spontaneous bacterial peritonitis (SBP). Additionally, recent studies suggested female gender as an independent risk factor for mortality in SBP.
- Trial name
- NCT03571711
- Testing
- Meropenem Injection
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Hannover Medical School
Elderly Infection
Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients
The investigator's purpose is to study the pharmacokinetics and pharmacodynamics of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients and recommend an individual dosage regimen of…
- Trial name
- NCT04799626
- Testing
- biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shandong University
Ventilator-associated Pneumonia, Hospital-acquired Pneumonia
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18 years of age with ventilated HABP or VABP.
- Trial name
- CERTAIN-2 (NCT06168734)
- Testing
- Cefepime-taniborbactam, Meropenem
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Central Nervous System Infections
Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment
A prospective, open-label study investigated the pharmacokinetic profile of meropenem in patients with post-neurosurgical central nervous system (CNS) infection, especially its BBB penetration into cerebrospinal fluid (CSF).
- Trial name
- NCT02506686
- Testing
- Meropenem
- Volunteers
- 82 people
- Sponsor
- Huashan Hospital
Sepsis
A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients
Meropenem is a powerful antibiotic used in intensive care for people who have very serious infections. Meropenem is rapidly removed from the blood by the kidneys and it is very expensive.
- Trial name
- MERO001 (NCT00891423)
- Testing
- Meropenem short infusion, Meropenem extended infusion
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Austin Health
Sepsis, Infection
Meropenem and Piperacillin Plasma Concentrations During CRRT
This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).
- Conditions
- Sepsis, Infection, Antibiotic, Renal Replacement Therapy
- Trial name
- ABC2 (NCT04203784)
- Testing
- Plasma concentration measurements
- Where
- Sweden
- Volunteers
- 135 people
- Sponsor
- Karolinska University Hospital
Sepsis
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
- Trial name
- NCT00318552
- Testing
- Meropenem
- Where
- 12 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Pfizer